Supplementary Table 1.

Summarized Treatment Outcome with EGFR-TKI of Individual Patients with Metastatic Lung Adenocarcinoma (n=96)

PFS, progression free survival; OS, overall survival; PR, partial response; SD, stable disease; PD, progressive disease; G, gefitinib; E, erolotinib; EGFR, epiderman growth factor receptor; TKI, tyrosine kinase inhibitor.

^*PFS was measured from the first day of treatment with EGFR-TKI to the progression or death.

^†OS was measured from the date of treatment with EGFR-TKI until the date of death.